Sage Therapeutics CMO Laura Gault resigns, effective March 21; CSO Quirk to lead clinical programs on interim basis

Sage Therapeutics, Inc.

Laura Gault, M.D., Ph.D. resigns as CMO effective March 21, 2025, to pursue a new opportunity.
Resignation is not due to any disagreement with Sage Therapeutics.
Mike Quirk, Ph.D., current CSO, will assume interim oversight of clinical development programs.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Laura Gault

Chief Medical Officer

Sage Therapeutics, Inc.

Effective: 2025-03-21
Filed: March 4, 2025, 6:59 PM ET

On March 3, 2025, Laura Gault, M.D., Ph.D. notified Sage Therapeutics, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company, effective March 21, 2025, to pursue a new opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Gault resigned as Chief Medical Officer at Sage Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On March 3, 2025, Laura Gault, M.D., Ph.D. notified Sage Therapeutics, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company, effective March 21, 2025, to pursue a new opportunity.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-25-045671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.